Clinical Practice Guidelines (CPG) on EBMonFHIR
1.0.2 - qa-preview

This page is part of the CPG-on-EBMonFHIR Implementation Guide (1.0.2).

PlanDefinition: Dexamethasone Application (Experimental)

Official URL: https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/example/covid19-dexamethasone-recommendation Version: 4.0
Active as of 2021-12-12 Responsible: CPGonEBMonFHIR Computable Name: Dexamethasone_Application

Application of Dexamethasone for ventilated patients only

Generated Narrative: PlanDefinition COVID19DexamethasoneApplication

knowledgeCapability: computable

knowledgeRepresentationLevel: structured

Action Combination Method

  • method: One or More

url: PlanDefinition Dexamethasone Application

version: 4.0

name: Dexamethasone_Application

title: Dexamethasone Application

type: Workflow Definition

status: Active

experimental: true

subject: Population_COVID19_Ventilated

date: 2021-12-12

publisher: CPGonEBMonFHIR

description:

Application of Dexamethasone for ventilated patients only

copyright:

RelatedArtifacts

-TypeClassifierResourceReference
*JustificationRecommendation ratingArtifactAssessment: extension = v4.0,active; date = 2020-01-03; artifact[x] = ->PlanDefinition Dexamethasone Application in ventilated COVID-19 patients
*CitationClinical practice guideline recommendationCitation DexamethasoneRecommendationCitation
*CitationClinical practice guidelineCitation COVID19_Intensive_Care_Treatment_Guideline

action

title: Dexamethasone Application

description:

Application of Dexamethasone: 6 mg once per day for 10 days p.o. or i.v. for ventilated COVID-19 patients

code: Guideline-based Care

definition: Dexamethasone Application in ventilated COVID-19 patients

action

title: No Dexamethasone Application

description:

No Dexamethasone Application for non-ventilated COVID-19 patients

code: Guideline-based Care

definition: No Dexamethasone Application for non-ventilated COVID-19 patients